BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» $21M investment raises Mesoblast’s hopes for a better year in 2017
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
$21M investment raises Mesoblast’s hopes for a better year in 2017
Dec. 30, 2016
By
Cormac Sheridan
and
Tamra Sami
No Comments
DUBLIN – Chicago Cubs fans excepted, 2016 has been a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm has had a torrid year.
BioWorld